■皮质类固醇对2019年冠状病毒病(COVID-19)幸存者急性期和随后6个月期间体液反应的影响尚不清楚。这项研究旨在确定使用皮质类固醇如何影响感染发作后6个月的COVID-19幸存者体液反应的开始和持续时间。
■我们使用了2020年1月在金银滩医院进行的洛匹那韦-利托那韦试验的动力学抗体数据,该试验涉及患有严重COVID-19住院的成年人(LOTUS,ChiCTR2000029308)。在住院期间收集了192名患者的抗体样本,在招募后的所有可用时间点监测动力学抗体.此外,在半年随访时,收集101例COVID-19幸存者的血浆样本进行全面的体液免疫检测.主要重点是比较接受全身性皮质类固醇治疗的患者与非皮质类固醇治疗组之间的体液反应。
■从发病到第30天,核蛋白(N)的受试者工作特征曲线(AUC)下的中位抗体滴度面积,刺突蛋白(S),和受体结合域(RBD)免疫球蛋白G(IgG)在皮质类固醇组中显著降低。N-的AUC,S-,与非皮质类固醇组相比,皮质类固醇组的RBD-IgM和中和抗体(NAb)在数值上较低。然而,N的峰值滴度,S,RBD-IgM和-IgG和NAb不受皮质类固醇的影响。在6个月的随访中,我们观察到大多数结合抗体的延迟下降,除N-IgM(β-0.05,95%CI[-0.10,0.00])外,虽然没有达到统计意义。对于NAb没有观察到显著差异。然而,半年血清阳性率,皮质类固醇显著加速了IgA和IgM的衰变,但对N,S-,和RBD-IgG或NAb。此外,与非皮质类固醇组相比,皮质类固醇组显示出病毒清除延迟的趋势,但结果无统计学意义(校正后的风险比0.71,95%CI0.50-1.00;P=0.0508).
■我们的研究结果表明,皮质类固醇治疗与抗体反应的起始受损有关,但这并没有损害结合和中和抗体的峰值滴度。在整个衰变阶段,从急性期到半年的随访,短期和低剂量皮质类固醇对体液反应没有显著影响,除了加速短寿命抗体的消退.
UNASSIGNED: The impact of corticosteroids on humoral responses in coronavirus disease 2019 (COVID-19) survivors during the acute phase and subsequent 6-month period remains unknown. This study aimed to determine how the use of corticosteroids influences the initiation and duration of humoral responses in COVID-19 survivors 6 months after infection onset.
UNASSIGNED: We used kinetic antibody data from the lopinavir-ritonavir trial conducted at Jin Yin-Tan Hospital in January 2020, which involved adults hospitalized with severe COVID-19 (LOTUS, ChiCTR2000029308). Antibody samples were collected from 192 patients during hospitalization, and kinetic antibodies were monitored at all available time points after recruitment. Additionally, plasma samples were collected from 101 COVID-19 survivors for comprehensive humoral immune measurement at the half-year follow-up visit. The main focus was comparing the humoral responses between patients treated with systemic corticosteroid therapy and the non-corticosteroid group.
UNASSIGNED: From illness onset to day 30, the median antibody titre areas under the receiver operating characteristic curve (AUCs) of nucleoprotein (N), spike protein (S), and receptor-binding domain (RBD) immunoglobulin G (IgG) were significantly lower in the corticosteroids group. The AUCs of N-, S-, and RBD-IgM as well as neutralizing antibodies (NAbs) were numerically lower in the corticosteroids group compared with the non-corticosteroid group. However, peak titres of N, S, RBD-IgM and -IgG and NAbs were not influenced by corticosteroids. During 6-month follow-up, we observed a delayed decline for most binding antibodies, except N-IgM (β -0.05, 95% CI [-0.10, 0.00]) in the corticosteroids group, though not reaching statistical significance. No significant difference was observed for NAbs. However, for the half-year seropositive rate, corticosteroids significantly accelerated the decay of IgA and IgM but made no difference to N-, S-, and RBD-IgG or NAbs. Additionally, corticosteroids group showed a trend towards delayed viral clearance compared with the non-corticosteroid group, but the results were not statistically significant (adjusted hazard ratio 0.71, 95% CI 0.50-1.00; P = 0.0508).
UNASSIGNED: Our findings suggested that corticosteroid therapy was associated with impaired initiation of the antibody response but this did not compromise the peak titres of binding and neutralizing antibodies. Throughout the decay phase, from the acute phase to the half-year follow-up visit, short-term and low-dose corticosteroids did not significantly affect humoral responses, except for accelerating the waning of short-lived antibodies.